奥昔布宁治疗前列腺癌雄激素剥夺治疗相关潮热的随机对照研究
这项随机对照研究纳入接受稳定ADT方案且每周至少28次潮热的前列腺癌患者,比较奥昔布宁2.5mg每日两次、5mg每日两次与安慰剂治疗6周的效果。主要终点为6周时患者报告的潮热评分较基线的变化。结果显示奥昔布宁优于安慰剂,且未发生治疗相关3级及以上不良事件。
要点
- 奥昔布宁5mg每日两次较安慰剂显著减少每日潮热次数和潮热评分。
- 奥昔布宁2.5mg每日两次在潮热评分上未达统计学显著差异。
- 奥昔布宁改善潮热相关日常干扰量表评分,且无治疗相关3级及以上不良事件。
核心结论
- 奥昔布宁在前列腺癌患者ADT相关潮热的管理中优于安慰剂。
研究设计与样本
- 随机对照研究,纳入接受稳定ADT方案且每周至少28次潮热的前列腺癌患者,随机分配至奥昔布宁2.5mg每日两次、5mg每日两次或安慰剂组治疗6周。
主要发现
- 最终分析患者平均每日潮热10.1次(标准差5.55),平均每日潮热评分为18.2(标准差13.5)。
- 未发生治疗相关3级及以上不良事件。
临床怎么用
- 对于接受ADT且潮热症状明显的前列腺癌患者,可考虑使用奥昔布宁改善潮热症状。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Hot flashes are a common side effect reported by men receiving androgen-deprivation therapy (ADT) for the treatment of prostate cancer. We sought to determine whether oxybutynin could improve hot flash symptoms in men with prostate cancer. PATIENTS AND METHODS: Patients with prostate cancer receiving a stable regimen of ADT with at least 28 hot flashes per week were randomly assigned to receive either oxybutynin 2.5 mg twice daily, oxybutynin 5 mg twice daily, or matching placebo for 6 weeks. The primary end point was the change in patient-reported hot flash scores since baseline at 6 weeks. Additional outcomes included incidence of adverse events (AEs), changes since baseline in Hot Flash-Related Daily Interference Scale (HFRDIS) scores, and patient-reported symptoms. RESULTS: Eighty-eight patients were enrolled, with the 81 participants eligible for final analysis reporting an average of 10.1 (standard deviation [SD], 5.55) hot flashes per day and an average daily hot flash score of 18.2 (SD, 13.5) included in final analysis. On average, patients on the placebo arm, 2.5 mg oxybutynin arm, and 5 mg oxybutynin arm had reductions in hot flashes/day of 2.15, 4.77 (P = .02), and 6.89 (P < .001), respectively. Daily hot flash scores for placebo, 2.5 mg oxybutynin, and 5 mg oxybutynin reduced by an average of 4.85, 9.94 (P = .07), and 13.95 (P = .002) points, respectively. No treatment-related grade 3+ AEs occurred. HFRDIS total scores improved by 14.2 and 20.7 points in the 2.5 mg (P = .042) and 5 mg (P < .01) oxybutynin arms, respectively, compared with a 3.1-point improvement with placebo. CONCLUSION: Oxybutynin is superior to a placebo for the management of ADT-associated hot flashes in men with prostate cancer.
引用
- Stish BJ, Mazza GL, Nauseef JT, et al. Alliance A222001: Oxybutynin Versus Placebo for the Treatment of Hot Flashes in Patients Receiving Androgen-Deprivation Therapy for Prostate Cancer. J Clin Oncol. 2026. PMID: 41587370. doi:10.1200/JCO-25-01486
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。